Finance

Cancer-focused biotech reports net loss for Q2, appoints new director to board

Published in Cancer Weekly, August 31st, 2004

EntreMed, Inc., (ENMD), a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer, reported results for the 3- and 6-month periods ending June 30, 2004.

The company also announced that James S. Burns, EntreMed president and CEO, has joined the company's board of directors.

The company reported a net loss for the second quarter of 2004 of $4.2 million, or $0.12 per share. This compares with a net loss of $5.3 million, or $0.19 per share, for the same period last year. Revenues for the second quarter 2004 were approximately $139,000 versus $286,000 for the comparable period a year ago.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry